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Increased FUs levels in astrocytes 
leads to astrocyte and microglia 
activation and neuronal death
Maria Antonietta Ajmone-Cat1, Angela onori2, Camilla toselli2,6, eleonora stronati2, 
Mariangela Morlando2, Irene Bozzoni2,6, emanuela Monni3, Zaal Kokaia3, Giuseppe Lupo  4, 
Luisa Minghetti  5, stefano Biagioni2,6 & emanuele Cacci  2
Mutations of Fused in sarcoma (FUs), a ribonucleoprotein involved in RNA metabolism, have been 
found associated with both familial and sporadic cases of amyotrophic lateral sclerosis (ALs). Notably, 
besides mutations in the coding sequence, also mutations into the 3′ untranslated region, leading 
to increased levels of the wild-type protein, have been associated with neuronal death and ALs 
pathology, in ALs models and patients. the mechanistic link between altered FUs levels and ALs-
related neurodegeneration is far to be elucidated, as well as the consequences of elevated FUs levels 
in the modulation of the inflammatory response sustained by glial cells, a well-recognized player in 
ALS progression. Here, we studied the effect of wild-type FUS overexpression on the responsiveness 
of mouse and human neural progenitor-derived astrocytes to a pro-inflammatory stimulus (IL1β) used 
to mimic an inflammatory environment. We found that astrocytes with increased FUS levels were 
more sensitive to IL1β, as shown by their enhanced expression of inflammatory genes, compared 
with control astrocytes. Moreover, astrocytes overexpressing FUS promoted neuronal cell death and 
pro-inflammatory microglia activation. We conclude that overexpression of wild-type FUS intrinsically 
affects astrocyte reactivity and drives their properties toward pro-inflammatory and neurotoxic 
functions, suggesting that a non-cell autonomous mechanism can support neurodegeneration in FUs-
mutated animals and patients.
Fused in sarcoma (FUS) or translocated in liposarcoma (TLS) is an ubiquitously expressed protein belonging to 
the family of heterogeneous nuclear ribonucleoproteins, continuously shuttling between the nuclear and cyto-
plasmic compartments, involved in pre-mRNA splicing, mRNA stability, and mRNA transport1–3.
FUS mutations have been identified in 4% of familial and 1% of sporadic amyotrophic lateral sclerosis (ALS) 
cases4–6. Moreover, FUS mutations are also associated with the ALS-related disorder frontotemporal dementia7.
Several mutations (e.g. FUS P525L, FUS P525R) affecting the C-terminus, lead to disruption of the nuclear 
localization signal, cause accumulation of FUS in the cytoplasm8, and are associated with a very aggressive and 
precocious form of ALS9. Of importance, mutations in the 3′ untranslated region (3′ UTR) of FUS, causing eleva-
tion of FUS in the wild-type (WT) configuration, have also been identified in a subset of ALS patients10,11.
Studies in different animal models indicate that increased expression of WT-FUS induces neurodegenera-
tion12. In accordance with findings in yeast and drosophila12–15, overexpression of human WT-FUS in mice causes 
an aggressive ALS phenotype, with progressive neuron degeneration and astrogliosis16, suggesting that the excess 
of WT-FUS is toxic for motorneurons (MNs). Mechanisms by which overexpression of WT-FUS causes motor 
neuron degeneration remain to be elucidated.
Several lines of evidence suggest that MN degeneration results from the combination of cell intrinsic MN 
vulnerability17,18, and the toxic effects of inflammatory response during disease progression19,20. Astrocytes 
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and microglia influence the progression of neurodegeneration in both ALS patients and mouse models of the 
disease21–29.
Gliosis with increased production of potentially harmful inflammatory mediators, including interleukin 1β 
(IL1β), tumour necrosis factor α (TNFα), interleukin 6 (IL6), prostanoids, and reactive oxygen species (ROS), 
was reported in the spinal cords of ALS patients19. In addition, upregulation of the transcription factor NF-kB, a 
master regulator of inflammation, was found in glial cells of both familial and sporadic ALS patients30–32.
FUS is involved in the pathogen responses in dendritic cells33 and it was shown to interact with NF-kB, specif-
ically the p65 subunit34, suggesting that mutation disrupting FUS sequence or levels may affect this pathway and 
the immune function of specialized cells.
The link between neuroinflammation and MN degeneration has been extensively explored in different ALS 
subtypes, but represents a novel, almost unexplored issue, in relation to FUS.
Here, we analyzed the effects of elevated levels of WT-FUS on astrocyte functional properties, focusing on 
their response to a pro-inflammatory stimulus, and on their cross-talk with microglia and neuronal cells. We 
used mouse and human neural progenitor cells isolated from fetal spinal cord (mNPsc or hNPsc, respectively), 
to generate astrocytes expressing increased levels of WT-FUS, under the control of a doxycycline-inducible pro-
moter. We found that several genes, including IL6, TNFα, prostaglandin-endoperoxide synthase 2 (PTGS2), and 
related proteins or metabolites were more abundantly expressed in astrocytes overexpressing FUS, and stimu-
lated with IL1β, indicating increased reactivity to this pro-inflammatory cytokine in comparison with control 
astrocytes. Furthermore, conditioned medium from cultured astrocyte-like cells overexpressing FUS potentiated 
pro-inflammatory microglia activation and increased neuronal cell death. Our data indicate that FUS upregu-
lation modulates the expression of several inflammatory genes, possibly through NF-kB activation, and confers 
neurotoxic potential to astrocytes in vitro.
Results
Establishment of FUS-overexpressing astrocyte-like cells of spinal cord origin, and assessment 
of exogenous FUS localization within cell compartments. To investigate the functional conse-
quences of WT-FUS overexpression in spinal cord astrocytes, we took advantage of the well-characterized model 
of mNPSC that can be efficiently differentiated into astrocyte-like cells, when treated with the morphogen BMP-4, 
as previously described by us and others35–40. The astrocytic differentiation under these conditions is further cor-
roborated by the up-regulation of typical astrocyte differentiation markers, such as GFAP, S100b, Aquaporin-4, 
FGF3 and Etv5, upon BMP-4 treatment, as reported in Supplemental Fig. 1.
mNPsc were engineered with plasmids allowing for the expression of human WT-FUS under doxycycline 
(Dox) control41, and differentiated into astrocyte-like cells by adding 25 ng/ml BMP-4 for 6 days, in the presence 
or in the absence of the selected dose of 50 ng/ml Dox (see Materials and Methods for details).
The transgenic protein, identified by immunostaining with an anti-Flag antibody, was mainly localized within 
nuclei, and its expression was tightly dependent on Dox treatment (Fig. 1A). The overexpression of the WT form 
did not significantly alter its subcellular localization.
As shown by Western blot, WT-FUS cells, administered with Dox for 48 and 72 hrs, showed a time-dependent 
increase of FUS levels of about 2.5- and 6-folds, respectively, compared to non-induced cells (Fig. 1B,C; see also 
Supplemental Fig. 2 for the original blot).
Elevation of WT-FUS modulates the expression of several inflammatory genes and increases 
NF-kB activation in response to IL1β. In order to analyze whether FUS overexpression determined 
astrogliosis, even in the absence of an inflammatory stimulus, we analyzed the accumulation in the culture media 
of relevant inflammatory proteins/metabolites usually upregulated in the inflammatory activation state. We 
focused on the free radical nitric oxide (NO), produced by the inducible enzyme iNOS, PGE2 - a major prostanoid 
produced by the inducible enzyme PTGS2 during brain inflammation42 -, and the pro-inflammatory cytokines 
TNFα and IL6, which have been found dysregulated in vivo in ALS mouse models and patients29,43.
In the culture media of WT-FUS overexpressing cells, the four metabolites (i.e. nitrite -taken as an index 
of NO production-, PGE2, TNFα, and IL6) remained under the detection limit of the specific assays used (see 
Methods section for details on the assays), as in the media of control cultures (−Dox), suggesting that elevated 
FUS levels did not change their basal expression (not shown).
To assess whether FUS overexpression changed the reactivity of astrocytes to a typical inflammatory stimulus, 
the cells were exposed to the pro-inflammatory cytokine IL1β, at the dose of 10 ng/ml for 24 hrs. mRNA expres-
sion analyses on cell extracts and metabolite specific assays on culture media were then performed. The dose of 
IL1β was selected based on the current literature, as the optimal dose to achieve astrocytes activation44–46.
As expected, following exposure to IL1β, all transcripts analysed by RT PCR on RNA cell extracts (iNOS, 
PTGS2, TNFα, and IL6) were upregulated in −Dox cultures (−Dox + IL1β), compared to unstimulated cultures 
(−Dox − IL1β) (Fig. 2A–D). As shown in panels B–D, their mRNA levels were further upregulated in WT-FUS 
overexpressing cells (+Dox + IL1β), with the exception of iNOS mRNA (panel A), whose induction was lower 
than in non-overexpressing cells (−Dox + IL1β).
Notably, a control RFP inducible cell line treated with Dox (+Dox + IL1β) (Supplemental Fig. 3), showed the 
same response to IL1β than non-induced cells (−Dox + IL1β), confirming the specific effect of FUS overexpres-
sion on gene regulation described in Fig. 2.
In accordance with mRNA data, PGE2 levels in the culture media of WT-FUS overexpressing cells (+Dox) 
were higher than in −Dox cultures (Fig. 2E), as assessed by a specific EIA assay.
ELISA analysis showed that IL1β stimulation also caused IL6 increase in the culture media of +Dox cells with 
respect to −Dox cultures (Fig. 2F), in accordance with the upregulation of the mRNA levels of the cytokine.
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As concerns TNFα and nitrite, their levels in culture media were near the limit of detection in all conditions, 
irrespectively from FUS induction and IL1β stimulation (not shown).
To deepen the analysis of astrocyte reactivity to IL1β upon FUS overexpression, we used the TaqMan array for 
mouse immune response, which allows simultaneous detection of the expression of 92 target genes from immune 
system functions that fall into 9 classes: Cell Surface Receptors; Stress Response; Oxidoreductases; Proteases; 
Transcription Factors; Signal Transduction; Cytokines and Cytokine Receptors; Chemokines and Chemokine 
Receptors; and Cell Cycle and Protein Kinases.
Inflammatory gene expression was compared between astrocyte-like cells overexpressing WT-FUS (+Dox) 
and control cells (−Dox), both stimulated with 10 ng/ml ILβ in the last 24 hours of differentiation with BMP-4. 
We found that that 45% of the genes were unchanged (41 genes), 37% expressed under the limit of detection 
(34 genes), 14% were upregulated (13 genes) and 4% down regulated (4 genes). Some of the unchanged genes 
showed relevant changes in their expression, though just missing significance (e.g. Cd68 3.4 ± 1, Cd80 8.5 ± 2.8, 
Sele 2.5 ± 0.5, Ly96 2.2 ± 0.4 fold change vs. −Dox). 18% of the analysed genes were significantly dysregulated 
(up- or down-regulated). In accordance with data presented in Fig. 2B–D, the upregulated genes included PTGS2 
(also known as COX-2), and the pro-inflammatory cytokines IL6 and TFNα. In addition, we found significant 
upregulation of the pro-inflammatory cytokines IL5, IL7, and IL15, and of colony stimulating factor 2 (CSF2), 
CD38, FN1, H2-Eb, Lrp2. Among the downregulated genes, besides iNOS (also known as nitric oxide synthase 2), 
as already shown in Fig. 2A, we found C-C Motif Chemokine Receptor 2 (Ccr2), C-X-C Motif Chemokine Ligand 
10 (Cxcl10), and Selp (Table 1).
It has been shown that FUS can interact with the p65 subunit of the transcription factor NF-kB, crucially 
involved in the regulation of inflammatory genes in glial cells, and activates NF-kB-mediated transcription in the 
human embryonic kidney 293-cell line34.
On these bases, as a possible mechanistic link for the increased reactivity of FUS overexpressing astrocytes to 
IL1β, we analysed whether FUS overexpression enhanced NF-kB activation in mNPsc-derived astrocytes.
Figure 1. Expression of FUS in NP-derived astrocytes. mNPsc electroporated with plasmids allowing for 
the conditional expression of human WT-FUS were maintained for six days in the presence of astrocyte 
differentiation medium supplemented with or without doxycycline (Dox) and then fixed and stained. (A) 
Exogenous FUS, identified by an anti-FLAG antibody, was localized in the nucleus (WT-FUS) only in cells 
exposed to Dox. Similar staining profile was obtained by using an antibody recognizing both endogenous 
and the exogenous FUS (anti-FUS antibody). Scale bar 30 μm. (B,C) Representative blot and quantification of 
relative FUS levels at 48 and 72 hrs upon doxycycline stimulation. The bar graph shows a significant increase 
of FUS expression in induced cells (+Dox) compared to control cells (−Dox). The band observed in the lanes 
−Dox reflects endogenous FUS expression. Values are expressed as the mean of two independent experiments. 
FUS levels are normalized with respect to β-actin.
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Cells were differentiated into astrocytes for 6 days as above, and stimulated during last 45 min with 10 ng/
ml IL1β (+Dox + IL1β). p65 activation, assessed by an ELISA-based assay, was increased in +Dox + IL1β cells 
as compared to −Dox + IL1β control cells (Fig. 2G), suggesting that FUS overexpression potentiates the NF-kB 
activation pathway elicited by IL1β.
FUS overexpression in human astrocyte-like cells increases the expression of inflammatory 
genes. We extended our analyses to astrocyte-like cells of human origin to validate the data obtained from 
Figure 2. Regulation of inflammatory genes and related proteins/metabolites in IL1β-activated murine WT-
FUS overexpressing astrocytes and relative controls, and determination of NF-kB p65 activation. (A–D) RT 
PCR analyses of iNOS (A), TNFα (Β), PTGS2 (C) and IL6 (D) mRNA expression upon IL1β stimulation in 
cultures treated or not with Dox, relative to unstimulated cells (−Dox − IL1β). Data show that TNFα (Β), 
PTGS2 (C) and IL6 (D) mRNA relative expression upon IL1β stimulation is higher, and that of iNOS (A) 
lower, in cells overexpressing WT-FUS (+Dox + IL1β), compared to non-overexpressing cells (−Dox + IL1β). 
Data are means ± SEM, n = 3–6, *P < 0.05 vs. −Dox + IL1β. (E,F) PGE2 and IL6 were quantified by EIA and 
ELISA assays, respectively, in the conditioned media collected from astrocyte-like cells differentiated in the 
presence or in the absence of Dox for 6 days and stimulated in the last 24 hrs with IL1β. In accordance with gene 
expression data, PGE2 and IL6 levels were higher in cells overexpressing WT-FUS (+Dox + IL1β) than in non-
overexpressing cells (−Dox + IL1β). Data are means ± SEM, n = 3, *P < 0.05 and **P < 0.005 vs. −Dox + IL1β; 
(G) NF-kB p65 activation, assessed by NFkB p65 ELISA-based kit on whole cell lysates, was increased in 
astrocyte-like cells overexpressing WT-FUS and treated with IL1β for 45 min before collection (+Dox + IL1β). 
Data are expressed as the percentage of activation respect to control cells (−Dox + IL1β) and are means ± SEM, 
n = 5, *P < 0.05.
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mouse NPsc-derived astrocytes and strengthen their relevance. We generated a human NP line (hNPsc), isolated 
from fetal spinal cord, and modified the cells to overexpress WT-FUS under Dox control.
hNPsc displayed mainly bipolar or multipolar morphology (Supplemental Fig. 4A) and under expansion con-
ditions expressed typical neural markers, such as Sox2 and Nestin (Supplemental Fig. 4B,C, respectively), while 
the expression of GFAP was undetectable in the majority of the cells (Supplemental Fig. 4D). Growth factor 
removal and administration of BMP-4 induced the expression of the astrocyte marker GFAP in about 70% of cells 
at 7 days (Supplemental Fig. 4E). hNPsc were also differentiated by removing growth factors; under this culture 
conditions around 20% of the cells showed neuronal morphology and expressed the neuronal marker MAP2 after 
7 days (data not shown). Altogether, these data demonstrate that hNPsc are multipotent.
FUS levels increased under both proliferating or differentiating conditions upon Dox administration (+Dox) 
compared to control cells (−Dox), as shown in Supplemental Fig. 5.
To assess the effects of FUS overexpression on the reactivity of hNPsc-derived astrocytes to IL1β, cultures 
were treated with the cytokine for 24 hrs and the mRNA levels of IL6, PTGS2, and iNOS were then analysed by 
RT-PCR. Representative images of IL1β treated cultures are shown in Fig. 3A. RT-PCR analysis demonstrated 
that, following 24 hrs of IL1β stimulation, the mRNA levels of IL6 and PTGS2 were higher in FUS-overexpressing 
hNPsc-derived astrocytes when treated with Dox (+Dox) as compared to untreated cells (−Dox) (Fig. 3B,C). 
These data are suggesting that, similar to what is observed in mouse cells, increased FUS levels enhance astrocyte 
reactivity. As for iNOS, its mRNA levels were not significantly modified between +Dox and −Dox conditions 
(Fig. 3D), most likely reflecting the different regulation of this gene in human cells as compared to mouse cells47.
Conditioned medium from mouse astrocyte-like cells overexpressing WT-FUS reduces neu-
ronal cell number and increases cell death. To assess whether FUS overexpressing astrocytes, showing 
enhanced production of inflammatory potentially neurotoxic molecules in response to IL1β, can damage neurons 
we assessed the effects of their conditioned media (CMs) on differentiated cultures.
Non-transgenic mNPsc were first differentiated for 10 days under culture conditions effective for the gen-
eration of neuronal cells, as previously described by us and others39,48; see also Materials and Methods). 
Differentiated cultures were then shifted in CMs obtained from 6 days differentiated astrocytes, grown in the pres-
ence (CM + Dox) or in the absence of Dox (CM − Dox) and stimulated with 10 ng/ml IL1β in the last 24 hrs (see 
Materials and Methods for details). As shown in Fig. 4, CM + Dox + IL1β treated cultures showed a significant 
reduction in the percentage of MAP2 (Fig. 4A,B) and an increase of activated Caspase-3 positive cells (Fig. 4B) 
as compared to CM − Dox + IL1β condition. To directly assess whether Caspase-3 activation was occurring in 
neuronal cells, CM-treated cultures were double stained for the neuronal marker βIII tubulin and Caspase-3 
(Fig. 4C). Similarly to what observed for MAP2, the percentage of βIII tubulin positive cells was decreased in 
CM + Dox + IL1β compared with CM − Dox + IL1β treated cultures (17.7 ± 2.5% and 26.2 ± 6.2% of total cell 
up regulated
(fold change)
down regulated
(fold change)
Ccr2 0.27 ± 0.03
Cd38 15 ± 2.7
Csf2 11.9 ± 2.5
Cxcl10 0.5 ± 0.05
Fn1 4 ± 0.4
H2-Eb1 2.5 ± 0.3
Icos 2.5 ± 0.4
Il15 3.7 ± 0.5
Il5 4.4 ± 0.7
Il6 3.0 ± 0.4
Il7 2.9 ± 0.4
Lrp2 4.1 ± 0.6
Nos2 0.4 ± 0.1
Ptgs2 2.6 ± 0.4
Selp 0.5 ± 0.1
Tnf 4.5 ± 0.8
Nfatc4 3.4 ± 0.5
Table 1. Inflammatory gene profiling of astrocyte-like cells expressing human WT- FUS. mNPsc were 
differentiated into astrocyte cells for six days with or without doxycycline (Dox) and stimulated in the last 24 
hrs with 10 ng/ml IL1β to assess the effect of FUS overexpression on astrocyte reactivity. The TaqMan Array 96-
well Mouse Immune Response Plate from Applied Biosystems was used to determine the expression of 92 genes 
from immune system functions (the complete list is reported at the manufacturer website). Gene expression 
levels were normalized for four different genes included in the TaqMan Array, and reported as the fold change 
respect to the levels in cells that were differentiated in the absence of doxycycline and stimulated with IL1β. 
Values are mean ± SEM (number of independent experiments n = 3). Each sample of each experiment was 
obtained by collecting RNA form three parallel cultures. Only genes showing significant regulation, as analysed 
by unpaired Student’s t-test at P < 0.05 are shown.
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number, respectively). Notably, some of the cells immunopositive for βIII tubulin, displaying severely impaired 
morphology, were also stained for Caspase-3 (Fig. 4C), suggesting that apoptotic cell death can account for neu-
ronal reduction in CM + Dox + IL1β treated cultures. However, few non-neuronal cells were also Caspase-3 
positive, suggesting that toxicity is not limited to neuronal cells but might also affect progenitors and/or other 
differentiated cells present in the culture.
Cultures treated with CMs from RFP cell line-derived astrocytes exposed to Dox and IL1β showed a percent-
age of neuronal positive cells (29.5 ± 2.3%) comparable to cultures treated with CMs from FUS-WT-derived 
astrocytes that had not been exposed to Dox, further confirming that, at least at the dose used, doxycycline does 
not interfere with astrocyte properties.
Overall, these data suggest that astrocytes overexpressing WT-FUS acquire a cytotoxic functional phenotype 
when exposed to a typical pro-inflammatory stimulus.
CMs from mouse astrocytes overexpressing WT-FUS increase the expression of pro-inflammatory 
markers in microglia. Reactive gliosis in the areas of motor neuron loss and inclusion pathology, in humans 
and in animal models, implicates cross-talk between astrocytes and microglia and their potential involvement in 
ALS progression and/or spreading. Therefore, we studied the effect of WT-FUS overexpression in astrocytes in 
relation to their cross-talk with microglia.
Primary microglial cultures were treated with CMs obtained from mNPsc-derived astrocytes, grown with or 
without Dox and then stimulated with IL1β for 24 hrs (CM + Dox + IL1β and CM − Dox + IL1β, respectively). By 
RT-PCR analysis, we found that the expression of the pro-inflammatory genes IL6, iNOS, and TNFα were higher 
in CM + Dox + IL1β treated microglia compared with either unstimulated cultures or cultures exposed to CMs 
from −Dox + IL1β astrocytes (Fig. 5A).
In accordance with gene expression data, we found that nitrites and IL6 released from microglia treated with 
CM + Dox + IL1β were significantly higher as compared to CM − Dox + IL1β treated cultures (Fig. 5B,C).
As described above, nitrite levels in astrocyte CMs were below the detection limit of the assay in all conditions; 
we can thus conclude that the levels measured in microglial media were produced by microglia itself.
As for IL-6, the Elisa kit used for detection of the cytokine in the culture media of rat microglia was spe-
cific for rat, and it is expected not to cross-react with IL6 from mouse astrocytes. In addition, the levels of the 
Figure 3. Expression of selected inflammatory genes in human NP-derived astrocytes. hNPsc were 
differentiated for six days with BMP-4, in the presence or in the absence of doxycycline (Dox) and stimulated 
in the last 24 hrs with IL1β. (A) Example of cultures processed for immunofluorescence and stained with an 
antibody directed versus the FLAG sequence of human WT-FUS (red) as a control of the efficient induction of 
transgene expression; in blue are Hoechst-stained nuclei. Scale bar 30 μm. (B–D) IL6, PTGS2 and iNOS mRNA 
relative levels were determined by RT-PCR in cells overexpressing FUS (+Dox + IL1β) or with normal levels 
of FUS (−Dox + IL1β). Data are expressed as fold change in gene expression, normalized to an endogenous 
gene (β-actin), and relative to cells that were not stimulated with IL1β (−Dox − IL1β), taken as 1. Data are 
means ± SEM, n = 3, *P < 0.05.
7Scientific RepoRts |          (2019) 9:4572  | https://doi.org/10.1038/s41598-019-41040-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
cytokine measured in mouse astrocyte CMs (see Fig. 2F) were far below the levels measured in rat microglial 
media (Fig. 5C). For these reasons, we can state that the levels shown in Fig. 5C are related, at least mostly, to IL6 
released by microglia.
Altogether, these data indicate that the overexpression of WT-FUS in mNPsc-derived astrocytes alters their 
cross-talk with microglia, upon IL1β-mediated activation, and determines the acquisition of a pro-inflammatory 
profile by microglia.
Previous studies have shown that prostanoid-mediated signaling controls microglial activation, and its inhi-
bition reduces motor neuron loss in mouse models of ALS49–51. In view of the upregulation of PTGS2 found in 
WT-FUS overexpressing astrocyte-like cells stimulated with IL1β, we addressed whether PTGS2-derived pros-
tanoids could be responsible for the enhanced reactivity of microglia exposed to their CMs. To this aim, we 
used the selective PTGS2 inhibitor, NS-398 at the concentration of 10 μM, to inhibit PTGS2 activity in WT-FUS 
overexpressing astrocytes. As expected, following NS-398 treatment, PGE2 levels accumulated in the CMs, as an 
index of PTGS2 activity, dropped under the detection limit of the EIA (Fig. 6A). Microglial cultures exposed to 
the CMs from NS-398 inhibited FUS-overexpressing astrocytes, produced levels of nitrite comparable to those of 
microglia exposed to CMs from not-inhibited astrocytes, indicating that microglia activation following exposure 
to CMs from FUS-overexpressing astrocytes was not dependent on increased prostanoids in their CMs (Fig. 6B).
Discussion
Glial contribution to MN degeneration is increasingly recognized in ALS-models and patients22,27,52; however, it 
is still not well established whether changes in WT-FUS levels due to mutations in the 3′UTR, as found in a subset 
of ALS patients, can affect glial properties and eventually sustain neuron degeneration. Although several studies 
indicate that high levels of wild-type FUS are toxic for MNs13–16, and MNn degeneration was demonstrated to be 
at least in part dependent on toxic gain of function in mouse models of ALS-FUS17,18, astrogliosis and microglio-
sis were also found in these same mice, as in SOD1 mice and ALS patients, suggesting that non-cell autonomous 
mechanisms can take place in FUS-mediated pathology, and contribute to disease progression. Our data clearly 
speak in favor of this possibility.
Here we showed that overexpression of WT-FUS in spinal cord astrocytes altered their reactivity to a 
pro-inflammatory stimulus, modified their cross-talk with microglia, and caused non-cell autonomous cell death.
FUS levels achieved in our cell model are comparable to those found in FUS-ALS mice overexpressing 
human WT-FUS16, supporting that our study can be informative of pathological mechanisms sustained by FUS 
overexpression.
Figure 4. Effects of conditioned media obtained from mouse NP-derived astrocyte-like cells on neuronal cell 
number and cell death. Non transgenic mNPsc were pre-differentiated for 10 days and then exposed for additional 
five days to CMs obtained from astrocyte-like cells (CM + Dox + IL1β or CM − Dox + IL1β). (A) Representative 
microphotographic fields showing neuronal cells stained with an anti-MAP2 antibody. Scale bar 30 μm. (B) 
Neuronal and activated Caspase-3 positive cell quantification. The percentage of MAP2 positive neuronal cells 
was reduced in cultures treated with CM + Dox + IL1β compared with CM − Dox + IL1β treated cultures; data are 
means ± SEM, n = 3, *P < 0.005 (paired Student’s T test). Immunocytochemical detection of activated Caspase-3 
showed that CM + Dox + IL1β increased cell death compared to CM − Dox + IL1β after three days of treatment. 
Quantification of Caspase-3 stained cells is given in the bar graph, and expressed with respect to CM − Dox + IL1β; 
data are means ± SEM, n = 3, *P < 0.0005. (C) Representative image showing cells immunostained for βIII tubulin 
(green) and Casp-3 (red). The arrowhead indicates a neuronal cell expressing activated Casp-3. Note also the 
presence of Casp-3 positive cells not expressing βIII tubulin (arrows). Scale bar 30 μm).
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Figure 5. Upregulation of pro-inflammatory genes in microglia exposed to the CMs from transgenic mNPsc-
derived astrocytes stimulated with IL1β. (A) RT-PCR analysis of the relative mRNA levels of iNOS, IL6 
and TNFα, in microglial cultures incubated for 24 hrs with the CMs of astrocyte-like cells, overexpressing 
FUS and stimulated with 10 ng/ml IL1β (CM + Dox + IL1β) or the CMs from non-overexpressing cells 
(CM − Dox + IL1β). Data, analyzed by the 2−ΔΔCt method using HPRT as the normalizing gene, are expressed 
as fold change vs unstimulated microglia, and are the means ± SEM, n = 4; *P < 0.05, **P < 0.005 for 
CM + Dox + IL1β vs CM − Dox + IL1β; paired Student’s T test. (B,C) Nitrite and IL6 levels accumulated after 
24 hrs in the medium of microglia treated with the CMs of astrocyte-like cells overexpressing or not FUS, 
and activated with IL1β as above (CM + Dox + IL1β and CM − Dox + IL1β). The CMs from FUS transgenic 
astrocytes induced higher release of both metabolites by microglia, consistently with the mRNA data. Data are 
the means ± SEM, n = 6; **P < 0.005.
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We found that in spinal cord NPs-derived astrocytes engineered to overexpress conditionally the wild-type 
sequence of the protein, FUS was mainly localized within nuclei, and only a very small fraction of the cells 
was faintly stained in the cytoplasm. Protein delocalization and intracytoplasmic inclusions have been found 
in FUS-associated ALS, either in neurons or glia4, and their formation was proposed as a mechanism driving 
neuronal degeneration. Our findings, in agreement with other studies showing that elevated WT-FUS remains 
predominantly in the nucleus11,18,43, demonstrate that deregulation of FUS expression in astrocytes, even in 
the absence of overt delocalization, can drive a relevant rearrangement of their inflammatory and neurotoxic 
properties.
The nuclear elevation of WT-FUS altered astrocyte reactivity, as revealed by the dysregulation of a panel 
of inflammatory genes in FUS overexpressing cells, compared to non-overexpressing astrocytes, in the pres-
ence of IL1β, used to mimic an inflammatory environment. In particular, the higher mRNA expression of 
pro-inflammatory cytokines (IL5-6-7-15, TFNα, CSF2), the inducible inflammatory enzyme PTGS2, adhesion 
molecules (FN1, ICAM), and the multi-ligand endocytic receptor LRP2, indicates the acquisition of a more 
reactive phenotype compared to non-overexpressing cells. On the other hand, the reduced expression of Ccr2, 
CxcL10, and iNOS, in activated FUS-overexpressing astrocytes (Table 1), may indicate an incomplete/dysregu-
lated acquisition of inflammatory functions in overexpressing astrocytes.
A variety of pro-inflammatory cytokines and growth factors, including IL-5 and IL-15, have previously been 
reported to be elevated in cerebrospinal fluid of patients with ALS53 and their abnormal expression has been asso-
ciated with ALS clinical status54. PTGS2, IL6, and TNFα were similarly found dysregulated in ALS mouse models 
and patients, further supporting the relevance of our findings.
Consistently with the enhanced mRNA expression of PTGS2 and IL6 in FUS overexpressing astrocytes, PGE2 
and IL6 protein levels were increased in their conditioned medium. TNFα, although increased at the mRNA 
level, was undetectable in the medium. In a recent study, analyzing the effects of the overexpression of FUSR521G 
mutation in primary astrocytes, Kia and colleagues43 found increased release of TNFα in the medium, and iden-
tified TNFα as a mediator of motor neuron toxicity. The lack of TNFα accumulation in the condition medium of 
the WT-FUS overexpressing astrocytes used in our study is likely reflecting different consequences of the overex-
pression of the mutated vs. the WT form of the protein. Alternatively, it could reflect a different maturational state 
between primary astrocytes used by43 and the astrocyte-like cells used in our study, or even regional differences 
in the areas of origin of these two astrocyte populations.
Our results extend previous observations and further establish that astrocytes with aberrant FUS expression 
can contribute to neuronal death upon activation with IL1β. Indeed, their conditioned medium led to a reduction 
in the percentage of neuronal cells, as evaluated by MAP2 and βIII tubulin stainings and an increase in activated 
Caspase-3 (Casp-3) stained cells. The identification of double labeled cells (Casp-3+/βIII tubulin+) indicates 
that at least part of the neuronal cells were dying through the activation of the apoptotic pathway. Several Casp-3 
positive cells were βIII tubulin negative, suggesting that cell death was also affecting other cell types in culture, 
such as neuronal progenitors and/or glial cells.
Among the multitude of factors into the CMs that could be responsible of cell toxicity, pro-inflammatory 
cytokines (e.g. IL6), found upregulated in FUS overexpressing astrocytes are potential good candidates, as sug-
gested by in vitro and in vivo models of different neuropathologies55,56. A possible dysregulation of the expression 
of neuroprotective factors could also contribute to the effect observed. The specific factors responsible for neuro-
toxicity were however not identified in the present study.
Figure 6. PTGS2 inhibition by NS-398 in transgenic astrocyte-like cells does not alter their capability to 
stimulate microglial activation. (A) mNPsc-derived astrocytes overexpressing FUS and treated for 24 hrs with 
10 ng/ml IL1β in the presence of the selective PTGS2 inhibitor NS-398 (10 μM), produced negligible amounts of 
PGE2, compared to non-inhibited cells, as assessed by EIA analysis. Data are means ± SEM, n = 3; *P < 0.05. (B) 
Nitrite levels in the medium of microglia exposed to CMs from FUS overexpressing cells treated with 10 ng/
ml IL1β in the presence of NS-398 (CM + Dox + IL1β + NS-398) were comparable to the levels induced by the 
CMs from non-inhibited astrocytes (CM + Dox + IL1β). Data are expressed as the fold increase versus nitrite 
levels produced by microglia exposed to CMs from non transgenic astrocytes (CM − Dox + IL1β), and are 
means ± SEM, n = 3.
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The striking functional and structural similarities between FUS and TAR DNA-binding protein-43 (TDP-43), 
which are both DNA/RNA binding proteins whose mutations have been linked to the pathogenesis of both ALS 
and frontotemporal dementia (FDT), suggest that abnormal functioning/expression of these two related proteins 
can be pivotal event in ALS and FTD8.
Interestingly, Tong and coworkers, previously showed that, similarly to what we observed with WT-FUS over-
expression, an increase in the expression of normal TDP-43 in astrocytes is sufficient to cause activation of astro-
cytes themselves and microglia, and non-cell-autonomous death of motor neurons57. In the same model, it was 
shown that motor neuron death likely involved deficiency in neuroprotective genes and induction of neurotoxic 
genes in astrocytes.
In addition, our data demonstrate that co-stimulatory molecules, such as CD38 and Icos, potently associated 
with T-cell activation and correlated with astrocyte ability to stimulate pro-inflammatory and immune regulatory 
patterns of cytokine production, were more upregulated in WT-FUS overexpressing astrocytes than in control 
cells. The co-stimulatory molecule CD80 was also induced in WT-FUS overexpressing cells, with an effect that 
just missed significance due to variability in the levels of induction among different cultures. Altogether, these 
observations suggest that WT-FUS overexpression may profoundly modify the cross talk of astrocytes with T-cells.
A global dysregulation of T-cell functions and immune changes have been related to an increased disease 
progression, decreased survival as well as production of pro-inflammatory effectors in experimental ALS and 
patients26,58. Interestingly, a recent transcriptomic analysis of motor cortex samples from sporadic ALS patients 
identified the upregulation of membrane protein-encoding genes involved in T-cell activation and proliferation 
(including ICOS and ICOS-L) in a subgroup of patients characterized by increased expression of genes involved 
in the inflammatory response59. From this perspective, the enhanced expression of costimulatory molecules found 
in FUS overexpressing astrocytes could be part of a pathogenic mechanism sustained by alterations of FUS levels.
The molecular mechanism underlying the enhanced expression of inflammatory and costimulatory genes 
in FUS overexpressing astrocytes requires further elucidations. However, our data indicate that the p65 subunit 
of NF-kB, a transcription factor crucially involved in the transcription of these genes and a master regulator of 
inflammation60, was more activated in murine FUS overexpressing astrocytes than in control cells. The similar 
upregulation of Nf-kB target genes in murine and human derived astrocytes overexpressing WT-FUS may suggest 
a common mechanism of NF-kB activation dependent on FUS in both cell types. Our results are consistent with 
previous data on the human embryonic kidney 293-cell line, in which FUS was shown to mediate transcription of 
NF-kB-dependent genes and to interact with p657,34. Similarly, in other tumor cell lines, the FUS-DDIT3 fusion 
oncogene was found to regulate NF-kB target genes61. FUS deregulation can thus elicit and/or contribute to the 
neuroinflammatory response in part by enhancing NF-kB activation, a mechanism also proposed for TDP-43 in 
ALS32. NF-kB and kinase signaling pathways were also found activated in familial and sporadic ALS astrocytes22.
A recent study revealed that the timing of astrocytic NF-kB activation drives a stage-specific neuroimmuno-
logical response in the SOD1 (G93A) ALS model: NF-kB activation promotes the expression of molecules that 
once released amplify microglial proliferation and protective functions in the presymptomatic phase of ALS, but 
also promotes detrimental microglial functions in the symptomatic phase62.
Besides astrocytes, microglial cells are increasingly recognized as crucial players in ALS pathology63, and 
microglial activation has been described in ALS patients and in animal models of ALS, including rodents carrying 
mutations of FUS16. As also suggested by the Ouali Alami et al. study62, the altered interaction of microglia with 
other immune cells26, and neurons themselves can profoundly affect the pathogenic process and its progression.
Notably, our study demonstrates that altered FUS expression in activated astrocytes alters their communi-
cation with microglia, as FUS-overexpressing astrocytes were able to induce activation of primary microglia 
more efficiently than control cells. Indeed, microglia exposed to astrocyte CMs upregulated the expression of 
typical pro-inflammatory mediators such as IL6, iNOS, and TNFα, suggesting a mechanism of amplification of 
the inflammatory response mediated by FUS, with the enhanced release of potentially harmful and neurotoxic 
molecules.
Pre-treatment of FUS overexpressing astrocytes with the selective PTGS2 inhibitor NS-398, did not halt 
the activation of microglia in response to astrocyte CMs, suggesting that under these conditions, other mole-
cules than prostanoids into the CMs were major players in modulating microglia activation. Among those, the 
pro-inflammatory cytokines IL6, IL5, IL7, IL15, found upregulated in FUS overexpressing astrocytes, are likely 
candidates as drivers of microglial activation by CMs, as well as other molecules possibly under astrocytic NF-kB 
transcriptional control.
Overall, our study adds further insights into the pathways modulated by FUS in glial cells and shows that 
elevated levels of the protein, mainly in the nucleus, can shape astrocyte properties, steering them toward a func-
tional phenotype that can affect neuronal survival and promote microglial activation, thus triggering a possible 
amplifying neurotoxic loop. As several mutations affecting FUS coding sequence cause protein delocalization 
with formation of intracytoplasmic inclusions and reduction in FUS nuclear levels, both gain of function in the 
cytoplasm and loss of function in the nucleus, have been proposed to participate into the sequential cascade cul-
minating into pathology64.
Studies from mouse models of FUS pathology, describing neurodegeneration in the absence of cytoplas-
mic pathology or significant mislocalization of FUS, strongly suggest that also nuclear gain of toxic function by 
mutant FUS may represent an important pathological mechanism65–67.
In the same line, our data show that retention/accumulation of aberrant levels of FUS into the nucleus can 
profoundly impair glial functions, likely by interfering with normal alternative splicing and/or transcription of 
target genes. A better understanding of the complex mechanisms underlying the control of glial functions and 
cross-talk with other cell types by FUS will contribute to identify common or unique cellular pathways involved 
in MN degeneration in different forms of ALS.
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Material and Methods
Cell cultures. Expansion and differentiation of mouse and human neural progenitor cells. Mouse neural pro-
genitor cells were previously derived from the spinal cord (mNPsc) of male and female CD1 mice at embryonic 
day E13.5, and grown as described in68–71.
Briefly, mNPsc were grown on 10 μg/ml poly-L-ornithine and 2,5 μg/ml laminin coated flasks in expansion 
medium constituted by DMEM/F12 (Gibco), supplemented with penicillin/streptomycin at 1:100 dilution (P/S; 
Sigma, Catalog # P4333, formulated as 100X concentration to contain 10,000 units penicillin and 10 mg strep-
tomycin/mL), 1:100 of 100x Glutamax (Gibco, Catalog # 35050061), 1:100 of N2 Supplement (Gibco, Catalog # 
17502001, provided as a 100X chemically defined formulation), 10 ng/ml basic fibroblast growth factor (bFGF; 
Peprotech) and 20 ng/ml epidermal growth factor (EGF; Peprotech).
mNPsc were differentiated into neurons by a previously established protocol. Under this culture condition, 
around 55% of the cells expressed markers and displayed morphology of neuronal cells39,72. Cells were plated at the 
density of 2 × 104 cells/cm2 and 24 hrs later expansion medium was replaced with neuronal differentiation medium 
containing DMEM/F12, 1:100 of 100x P/S, 1:100 of 100x Glutamax, 10 ng/ml bFGF, 1:100 of 100x N2S, 1:50 of 
50X B27 (Gibco, Catalog # 17504, provided as a 50X serum-free supplement) and 1 μM N-[(3,5-difluorophenyl)
acetyl]-lalanyl-2-phenyl]glycine-1,1-dimethylethyl ester (DAPT; Tocris). The whole medium was replaced once 
during the first 6 days of differentiation. Then cells were differentiated for additional 4 days in fresh medium 
withdrawn of growth factors and additioned with 20 ng/ml brain derived neurotrophic factor (BDNF; Peprotech).
mNPsc were differentiated into astrocyte-like cells by replacing expansion medium with astrocyte differentia-
tion medium constituted by DMEM/F12 containing 1:100 of 100x N2S, 1:50 of 50x B27, 1:100 of 100x Glutamax, 
1:100 of 100x P/S, and 25 ng/ml mouse bone morphogenetic protein-4 (BMP-4; Peprotech). The whole medium 
was changed every 3 days with fresh medium. Under these culture conditions, more than 90% of the cells 
expressed the glial marker GFAP, and neuronal cells were virtually absent (see also36,39).
The human neural progenitor cell line was derived from the spinal cord (hNPsc) of a 9 week post-conception 
fetus. Fetuses were obtained from Lund and Malmö University Hospitals, according to guidelines approved by the 
Lund/Malmö Ethical Committee. Informed consent for donation of foetal tissue was obtained from the mother.
Specifically, the human line was derived from P0 neurospheres. hNPsc were expanded according to a previ-
ously established protocol73. Cells were plated on 0.1 μg/ml poly-L-ornithine and 10 μg/ml laminin coated flasks, 
and grown in human expansion medium constituted by DMEM/F12 supplemented with 1:50 of 50x B27 minus 
vitamin A (Gibco), 1:100 of 100x P/S, 1:100 of 100x Glutamax, 10 ng/ml bFGF (R&D) and 10 ng/ml EGF (R&D).
For hNPsc differentiation, cells were plated at the density of 1 × 104 cells/cm2 in human expansion medium, 
and 24 hours later switched in a medium containing 1:100 of 100X N2S, 1:50 of 50x B27 (Gibco), 1:100 of 100x 
P/S, 1:100 of 100x Glutamax and supplemented with 20 ng/ml human recombinant BDNF, or 25 ng/ml human 
recombinant BMP-4 (Peprotech).
Generation of stably engineered cell lines. For the generation of stable mNPsc lines overexpressing wild-type FUS 
or the red fluorescent protein (RFP), cells were engineered with the appropriated plasmids, which allowed for the 
doxycycline inducible expression of the genes of interest41.
Plasmids were delivered into the cells by electroporation (Nucleofector; Lonza), according to manufacturer’s 
instruction (see also39,69 for further details) and selected with puromycin (1 μg/ml).
mNPsc-RFP cells were used to determine the effective dose of doxycycline to induce transgene expression. 
The dose of 50 ng/ml was chosen as the lowest, among the tested doses, able to induce the transgene expression in 
a very consistent number of cells (about 80–85%), without affecting cell survival, proliferation and expression of 
selected inflammatory genes (data not shown).
Similar procedures and doses of antibiotics for cell selection and gene induction were used during the gener-
ation of stably transfected hNPsc lines.
Primary microglial cultures. Primary microglia was obtained from mixed glial cultures prepared from the cere-
bral cortex of 1-day-old male and female Wistar rats (RRID:RGD_13508588) from Charles River following pre-
viously published protocols74 and in accordance with the European Communities Council Directive N. 2010/63/
EU and the Italian Law Decree n° 26/2014 (authorization from Ministry of Health:152/2016-PR).
In brief, mixed cultures were maintained for 11 days in Basal Eagle’s Medium (BME, Gibco, Catalog # 41010), 
supplemented with 10% heat-inactivated foetal bovine serum (FBS, ultra-low endotoxin, South American Origin, 
EuroClone, Catalog # ECS0186L), 2 mM L-glutamine (Gibco, Catalog # 25030081, provided as a 200 mM stock 
solution) and 100 μg/ml gentamicin (basal medium). After this time, microglial cells were harvested by mild 
shaking, resuspended in basal medium, and seeded on uncoated plastic wells at the density of 1 × 105 cell/cm2. 
Cell viability was greater than 95%, as tested by Trypan Blue exclusion. Immunostaining revealed that cultures 
consisted of 96% positive cells for the microglia/macrophage marker CD68. After 24 hrs in culture, basal medium 
was replaced with the CMs from transgenic mNPsc, and the cells incubated for additional 24 hrs. The media were 
then collected and stored at −70 °C until subsequent analyses.
preparation of conditioned media and RNA. Transgenic mNPsc were maintained in astrocyte differenti-
ation medium for 6 days, in the presence or in the absence of 50 ng/ml of doxycycline. Cells were then washed three 
times with PBS and cultured for the last 24 hrs in a medium constituted by DMEM/F12, 1:100 of 100x P/S, 1:100 of 
100x Glutamax, 1:50 of 50x B27, 1:100 of 100x N2S and 10 ng/ml IL1β, without doxyclycline to avoid its potential 
confounding effects. CMs were collected, centrifuged at 1500 rpm for 5 min and stored at −20 °C. The cells were 
lysed in Trizol (Sigma-Aldrich) for total RNA extraction and subsequent gene expression analyses (see below).
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Thawed CMs were assessed for cytokines, nitrite, and prostaglandin E2 (PGE2) levels, and for their effects on 
neuronal or microglia cells, as described below.
NF-kB p65 activation assay. NF-kB activation was assessed in 6 days differentiated astrocyte-like cells (see 
above), stimulated, 45 min before being collected, with 10 ng/ml of IL1β in fresh medium.
Proteins were collected by using an extraction kit (Active Motif, Catalog # 40010), according to manufacturer’s 
instruction. The whole-cell lysates from mNPsc were concentrated by means of Amicon Ultra-0.5 centrifugal filter 
devices (Millipore) to achieve the recommended concentration of 20 μg of protein per well per sample (20 μl vol-
ume). The protein concentration was determined before and after concentration, by the BCA protein assay (Pierce).
NF-kB activation in whole-cell lysates was determined by the TransAM NFkB p65 kit (Active Motif, Catalog 
# 40096), following the manufacturer’s instructions. This 96 well ELISA-based kit provides colorimetric readout 
of NF-kB p65 subunit activation, quantified by spectrophotometry at the wavelength of 450 nm (reference wave-
length 655 nm). As a positive control for p65 activation, Jurkart nuclear extracts, provided with the kit, were used. 
Detection limit: <1 μg lysate/well.
Cytokines, pGe2 and No determination. Specific ELISAs for mTNFα, mIL6 (Thermo Scientific, Catalog 
# EMTNFA and # EM2IL6, respectively), rIL6 (PicoKine ELISA Kit, Boster Biological Technology, Catalog # 
EK0412), and high sensitivity enzyme immunoassay (EIA) for PGE2 (Assay Designs; Catalog # 931-001) were 
used to assay cytokines and PGE2 levels in CMs from transgenic mNPsc and microglia, following the manu-
facturer’s instructions. The ranges of determination are: 50–2450 pg/ml for mTNFα, 7.8–500 pg/ml for mIL6; 
62.5–4000 pg/ml for rIL6; 7.8–1000 pg/ml for PGE2.
The production of nitric oxide (NO) was determined by measuring the content of nitrite, one of the end prod-
ucts of NO oxidation in the media, as previously described75. All chemical for the NO assay were from Sigma.
Immunocytochemistry. Immunocytochemistry was performed on NPsc fixed with 4% paraformaldehyde 
(PFA) in PBS for 15 min at room temperature. After fixation, cultures were washed with PBS and then incubated 
in PBS containing 5% of the appropriate normal serum and 0.025% Triton X-100 (preincubation solution) for 1 h 
at room temperature.
Subsequently, cultures were incubated at 4 °C overnight in the preincubation solution containing the pri-
mary antibodies listed below. Cells were washed 3 times with PBS and incubated for 1 h at room temperature 
in the incubating solution containing 10 μg/mL Hoechst 33342 and the appropriate alexa fluor 488- and/or 
Cy3-conjugated (Jackson Immunoresearch) secondary antibodies at dilution 1:200. After rinsing with PBS, cells 
were coverslipped with DAKO mounting medium (Dako).
The following primary antibodies were used: rabbit polyclonal anti-FLAG (1:1000; Sigma, RRID:AB_439687); 
mouse monoclonal anti-FUS (1:1000; Santa Cruz, RRID:AB_2105208); mouse monoclonal anti-SOX-2 (1:50; 
R&D Systems, RRID:AB_358009); mouse monoclonal anti-nestin (1:200; Millipore, RRID:AB_11211837); mon-
oclonal anti-beta III tubulin (1:500; Promega, RRID:AB_430874); mouse monoclonal anti-S100b (1:100; Abcam, 
RRID:AB_1142710); rabbit polyclonal anti-MAP-2 (1:500; Millipore, RRID:AB_91939); rabbit polyclonal 
anti-Caspase 3 (1:20; Millipore, RRID:AB_91556); rabbit polyclonal anti-GFAP (1:200; Cell signaling Technology, 
RRID:AB_2631098); mouse monoclonal anti βIII tubulin (1:500; Promega, RRID:AB_430874). Validation data 
for the antibodies are available from the companies.
The percentages of immunopositive cells for differentiation or apoptotic markers (such as Caspase-3), in the 
different experimental conditions, were determined by counting immunolabeled cells in at least 10–15 micros-
copy randomly chosen fields of 3 different microscope slides for each condition, in at least 3 independent exper-
iments. The samples were large enough to minimize the statistical impact of rare outliers in each group. The 
investigator in charge of counting was blinded to experimental groups. Groups were identified by letters, and the 
code was disclosed at the end of the analyses.
Western blotting. Cells were lysed and harvested in RIPA buffer (320 mM Sucrose, 50 mM TRIS pH 7.5, 
1% Tryton, 10% glycerol and 1% of inhibitor of proteases cocktail (Sigma-Aldrich), incubated on ice for 30 min 
and centrifuged for 12 min at 13000 g. Protein amounts were quantified by Bradford assay (Bio-Rad) and 10 μg 
of proteins were subjected to SDS-polyacrylamide gel electrophoresis (4% and 10% for stacking and running 
gel, respectively) transferred overnight onto polyvinylidene fluoride membrane (Immobilion-PSQ, Millipore). 
Membranes were blocked in 5% non-fat dry milk and then incubated with the following primary antibodies: 
monoclonal anti-FUS (1:700, Santa Cruz) and anti-beta-Actin (1:10000, Sigma-Aldrich, RRID:AB_476744). 
Blots were washed twice, incubated with the appropriate horseradish peroxidase secondary antibodies for 2 hrs 
(1:10000, Jackson Immunoresearch), and after three additional washing steps, incubated in lumi-light enhanced 
chemiluminescence substrate (Bio-Rad) and exposed into Chemidoc (Bio-Rad). Densitometric analyses on 
scanned blots were performed using the ImageLab program (Bio-Rad). Row western blotting images are provided 
as supporting document.
Quantitative real-time polymerase chain reaction (Rt-pCR) analysis. Total RNA was extracted 
with the Trizol extraction procedure (Invitrogen, Carlsbad, CA); to remove any traces of genomic DNA, total 
RNA was treated with DNAse I (Ambion, Grand Island, NY). For each RNA sample, 1 μg total RNA was reverse 
transcribed with random hexamers (Promega) and MMLV reverse transcriptase (Promega)71.
For inflammatory gene expression in mNPsc-derived astrocytes, overexpressing or not WT-FUS in the pres-
ence of IL1β, we used the TaqMan Array 96-well Mouse Immune Response Plate (Catalog # 4414079). Gene 
expression was performed by using TaqMan Universal Master mix II (Applied Biosystem) on a 7500 RT-PCR 
(Applied Biosystems). The values obtained were normalized for the four different genes (18S, Gapdh, Gusb, 
Hprt1) included in the TaqMan Array plate and expressed as fold change over non-overexpressing cells.
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For RT-PCR analyses of selected genes in mNPsc- and hNPsc-derived astrocytes and in rat microglia, we used 
the following primer pairs:
Primer sequences (mouse):
mβ–actin: For GCGCAAGTACTCTGTGGA Rev AAGGGTGTAAACGCAGCT
mGFAP: For CGAAGAAAACCGCATCACCAT Rev GGCCTTCTGACACGGATTTG
mS100β: For TGCCCTCATTGATGTCTTCCA Rev GAGAGAGCTCGTTGTTGATAA
mAquaporin 4: For GAGTCACCACGGTTCATGGA Rev CGTTTGGAATCACAGCTGGC
mNestin: For TGCCGAAGAGCTGGAGAG Rev CTCGCAGAGCCTCTAACTCG
mEtv5: For GGGAGAGACAAAAACCACCA Rev GCGCTAACCCTGAACACACT
mFGFR3: For CTTCAGTGTGCGTGTAAC Rev CGTTTGGAATCACAGCTGGC
mTNFα: For CATCTTCTCAAAATTCGAGTGACAA Rev TGGGAGTAGACAAGGTACAACCC
mIL6: For GAGGATACCACTCCCAACAGA Rev AAGTGCATCATCGTTGTTCATACA
miNOS: For TCTTCGGTGCAGTCTTTTCC Rev GTGCCAGAAGCTGGAACTCT
Primer sequences (human):
hβ–actin: Qiagen
hFUS: For GCTGCCATCACAAGCATAGC Rev CAGCCTGGATGACAGAGCAA
hIL6: For CTCAGCCCTGAGAAAGGAGA Rev TTTCAGCCATCTTTGGAAGG
hPTGS2: For CGCTCAGCCATACAGCAAAT Rev CCGGGTACAATCGCACTTAT
hiNOS: For ACAAGCCTACCCCTCCAGAT Rev TCCCGTCAGTTGGTAGGTTC
Primer sequences (rat):
rHPRT: For CTCATGGACTGATTATGGACAGGAC Rev GCAGGTCAGCAAAGAACTTATAGCC
rIL6: For TCCTACCCCAACTTCCAATGCTC Rev TTGGATGGTCTTGGTCCTTAGCC
rTNFα: For AAATGGGCTCCCTCTCATCAGTTC Rev TCTGCTTGGTGGTTTGCTACGAC
riNOS: For GCC ACC TCG GAT ATC TCT TG Rev TCT GGG TCC TCT GGT CAA AC
Annealing temperature was 60 °C for all the primer pairs listed. All samples were run in triplicate, and each 
well of PCR contained 20 μl as a final volume of reaction, including 2 μl of cDNA corresponding to 20 ng of total 
RNA, 0.75 μM of each primer and 10 μl of PCR master mix. Thermal cycling conditions were as follow: 1 cycle at 
95 °C for 10 min; 40 cycles 95 °C for 15 sec and 60 °C for 1 min.
Expression levels of genes of interest were compared between culture conditions using the Relative 
Quantification (ΔΔCt) Study of Applied Biosystems 7500 System SDS Software. HPRT or β-actin were used as 
internal control genes and amplification specificity was checked using a melting curve, following the manufac-
turer’s instructions.
statistical analysis. Data are expressed as mean ± SEM of at least three independent experiments (run in 
triplicates). Exact numbers (n) for all the experiments are provided in the figure legends.
The experimental design and the statistical analysis of the data in this study followed the methodology and 
the standards usually used in explorative in vitro studies. In the experimental models adopted, external sources 
of variability are controlled, and residual variability arises from random error of replicates, as also demonstrated 
by the low SEM. On these bases, we adopted two-sided Student’s t-test as the more powerful test to evidence 
possible differences between two groups. GraphPad Prism software was used. P values ≤ 0.05 were considered 
as significant.
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